Private equity firm Inflexion has completed an investment in the UK’s Pangaea Laboratories, owner of the Medik8 skin care brand.
The investment is being made by Inflexion Buyout Fund V, the company’s dedicated mid-market fund.
Founder-led Pangaea boasts two facilities in Hertfordshire, where Medik8 products are developed and manufactured.
The premium skin care brand is focused on science-based skin ageing products and it hopes the investment will enable it to focus on enhancing its relationships within the professional beauty industry while growing digital channels in new international markets.
“In the last three years, the brand has experienced phenomenal growth as the skin care consumer has become more knowledgeable and moved towards science and ingredients,” said Elliot Isaacs, Founder of Medik8.
“We are thrilled to be partnering with Inflexion who have the passion and expertise to help us accelerate the brand’s international ambitions.
“Crucially, Inflexion have been unwavering in their support for our amazing team and professional-led heritage. We could not be more excited about the future.”
Simon Turner, Managing Partner of Inflexion, commented: “Medik8’s science-based approach to skin care combined with its sustainability credentials make it an incredibly impressive business.
“We look forward to working closely with the whole team to scale the business further through enhancing their digital routes to market, and by supporting their continued innovation, new product launches and international expansion.”
Founded in 1999, Pangaea's latest launch from Medik8 is Sleep Glycolic, an at-home 10% glycolic acid peel that is said to deliver unparalleled resurfacing results while the user sleeps, but with zero downtime.
Designed for use two to three times a week, Sleep Glycolic deeply refines skin overnight for instant brightening, smoothing and decongesting results the morning after use.